Avalon GloboCare (ALBT) said Tuesday it received a notice of allowance from the China National Intellectual Property Administration for its patent application covering a technology designed to "enhance" the expansion, manufacturing, survival, and efficacy of chimeric antigen receptor, or CAR-T and CAR-natural killer cells.
The company said it co-developed the patent with Hong Kong-based Arbele.
Avalon GloboCare shares were up 7.3% in recent trading.
Price: 3.96, Change: +0.27, Percent Change: +7.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。